American gastroenterological association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

Gastroenterology

Volumn 130, Issue 3, 2006, Pages 940-987

  Lichtenstein, Gary R ^{a,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac,ad}   Abreu, Maria T ^{b,e,s,v,ac,ae}   Cohen, Russell ^{c,e,f,i,j,o,t,v,y,aa,ae,af,ag,ah,ai}   Tremaine, William ^d,aa,ae,af  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d Mayo Clinic   (United States)

^e Abbott Corporation   (United States)

^f Astra Zeneca Inc   (United States)

^g Axcan Corporation   (United States)

^h Berlex   (United States)

ⁱ CENTOCOR INC   (United States)

^j Elan   (United States)

^k Genetics Institute   (United States)

^l GLAXOSMITHKLINE   (United States)

^m Inkine Inc   (United States)

ⁿ Intesco Corporation   (United States)

^o ISIS Corporation   (United States)

^p Millenium Pharmaceuticals   (United States)

^q Otsuka Corporation   (Japan)

^r Proctor and Gamble Pharmaceut Div   (United States)

^s Prometheus Laboratories Inc   (United States)

^t Protein Design Labs   (United States)

^u Protomed Scientific   (United States)

^v Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

^w Schering Plough Corporation   (Germany)

^x Serono   (United States)

^y Shire Pharmaceuticals   (United States)

^z Smith Kline Beecham Corporation   (United States)

^aa SOLVAY   (Belgium)

^ab Synta Pharmaceuticals   (United States)

^ac UCB New Medicines   (United States)

^ad Chemical and Screening Sciences   (United States)

^ae PROCTER AND GAMBLE COMPANY   (United States)

^af Kenwood ^*

^ag Kenwood   (United States)

^ah Gray and Rice Strategic Communications   (United States)

^ai Pfizer

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CORTICOTROPIN; CORTISONE; CYCLOSPORIN; CYCLOSPORIN A; FUROSEMIDE; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TSUKUBAENOLIDE;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ACNE; ADRENAL HEMORRHAGE; ADRENAL INSUFFICIENCY; ALLERGIC PNEUMONITIS; ALLERGIC REACTION; ALOPECIA; ANKLE EDEMA; ARTHRALGIA; ARTHRITIS; BACTERIAL MENINGITIS; BLADDER TUMOR; BONE DENSITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE NECROSIS; BREAST TUMOR; CANDIDIASIS; CAPILLARY RESISTANCE; CATARACT; CELLULITIS; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COLITIS; CONTROLLED DRUG RELEASE; COUGHING; CREATININE BLOOD LEVEL; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DELAYED HYPERSENSITIVITY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG METABOLISM; DRUG RECEPTOR BINDING; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ELECTROLYTE DISTURBANCE; EMBRYOTOXICITY; ENCEPHALITIS; ENTERITIS; ERYTHEMA; EUROPE; FEVER; FIRST PASS EFFECT; FLATULENCE; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; HEALTH CARE PERSONNEL; HERPES ZOSTER; HIRSUTISM; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INSOMNIA; INTRACRANIAL HYPERTENSION; KIDNEY TUMOR; LEG CRAMP; LEUKEMIA; LEUKOPENIA; LISTERIOSIS; LIVER ABSCESS; LIVER DISEASE; LIVER FIBROSIS; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SOCIETY; META ANALYSIS; MOOD DISORDER; MOON FACE; MYALGIA; MYCOSIS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NOCARDIOSIS; NODULAR HYPERPLASIA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PATIENT CARE; PETECHIA; PHLEBITIS; PNEUMONIA; POPULATION BASED CASE CONTROL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROCTITIS; PRURITUS; PSYCHOSIS; PURPURA; Q FEVER; RASH; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; SPLEEN DISEASE; STRIA; SYSTEMATIC REVIEW; TERATOGENICITY; THORAX PAIN; THROMBOCYTOPENIA; TOXIC HEPATITIS; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VIRUS HEPATITIS; VOMITING; WEIGHT GAIN;

EID: 33644869450     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.01.048     Document Type: Article

References (315)

1. B. Crohn, L. Ginzburg, G.R. Oppenheimer Regional ileitis A pathologic and clinical entity JAMA 99 1932 1323 1329
2. Wilks S, Moxon W. Lectures on pathological anatomy. 2nd ed. Philadelphia, PA: Lindsay and Blakiston, 1875.
3. A. Amsterdam, K. Tajima, R. Sasson Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action Biochem Pharmacol 64 2002 843 850
4. A.R. Clark, M. Lasa Crosstalk between glucocorticoids and mitogen-activated protein kinase signaling pathways Curr Opin Pharmacol 3 2003 404 411
5. M. Kagoshima, K. Ito, B. Cosio, I.M. Adcock Glucocorticoid suppression of nuclear factor-kappa B: a role for histone modifications Biochem Soc Trans 31 2003 60 65
6. K. De Bosscher, W. Vanden Berghe, G. Haegeman The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression Endocr Rev 24 2003 488 522
7. R. Hayashi, H. Wada, K. Ito, I.M. Adcock Effects of glucocorticoids on gene transcription Eur J Pharmacol 500 2004 51 62
8. N.J. Goulding The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus Curr Opin Pharmacol 4 2004 629 636
9. F. Buttgereit, K.G. Saag, M. Cutolo, J.A. da Silva, J.W. Bijlsma The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis Scand J Rheumatol 34 2005 14 21
10. R.I. Scheinman, P.C. Cogswell, A.K. Lofquist, A.S. Baldwin Jr Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids Science 270 1995 283 286
11. Y. Tao, C. Williams-Skipp, R.I. Scheinman Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis J Biol Chem 276 2001 2329 2332
12. R. Lofberg, A. Danielsson, O. Suhr, O. Suhr, A. Nilsson, R. Schioler, A. Nyberg, R. Hultcrantz, B. Kollberg, R. Gillberg, R. Willen, T. Persson, L. Salde Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis Gastroenterology 110 1996 1713 1718
13. S. Bar-Meir, Y. Chowers, A. Lavy, A. Lavy, D. Abramovitch, A. Sternberg, G. Leichtmann, R. Reshef, S. Odes, M. Moshkovitz, R. Bruck, R. Eliakim, E. Maoz, U. Mittmann Budesonide versus prednisone in the treatment of active Crohn's disease The Israeli Budesonide Study Group Gastroenterology 115 1998 835 840
14. E. Dahlberg, A. Thalen, R. Brattsand, R. Brattsand, J.A. Gustafsson, U. Johansson, K. Roempke, T. Saartok Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids Mol Pharmacol 25 1984 70 78
15. C.M. Spencer, D. McTavish Budesonide A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease Drugs 50 1995 854 872
16. A. Miller-Larsson, B. Gustafson, C.G. Persson, R. Brattsand Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat Aliment Pharmacol Ther 15 2001 2019 2025
17. S. Edsbacker, B. Bengtsson, P. Larsson, P. Larsson, P. Lundin, A. Nilsson, J. Ulmius, P. Wollmer A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules Aliment Pharmacol Ther 17 2003 525 536
18. P.D. Lundin, S. Edsbacker, M. Bergstrand, M. Bergstrand, J. Ejderhamn, H. Linander, L. Hogberg, T. Persson, J.C. Escher, B. Lindquist Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease Aliment Pharmacol Ther 17 2003 85 92
19. G.R. Greenberg, B.G. Feagan, F. Martin, F. Martin, L.R. Sutherland, A.B. Thomson, C.N. Williams, L.G. Nilsson, T. Persson Oral budesonide for active Crohn's disease Canadian Inflammatory Bowel Disease Study Group N Engl J Med 331 1994 836 841
20. O.O. Thomsen, A. Cortot, D. Jewel, J.P. Wright, T. Winter, F.T. Veloso, M. Vatn, T. Persson, E. Pettersson A comparison of budesonide and mesalamine for active Crohn's disease International Budesonide-Mesalamine Study Group N Engl J Med 339 1998 370 374
21. P. Rutgeerts, R. Lofberg, H. Malchow, C. Lamers, G. Olaison, D. Jewell, A. Danielsson, H. Goebell, O.O. Thomsen, H. Lorenz-Meyer, H. Hodgson, T. Persson, C. Seidegard A comparison of budesonide with prednisolone for active Crohn's disease N Engl J Med 331 1994 842 845
22. V. Gross, T. Andus, I. Caesar, S.C. Bischoff, H. Lochs, A. Tromm, H.J. Schulz, U. Bar, A. Weber, M. Gierend, K. Ewe, J. Scholmerich Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease German/Austrian Budesonide Study Group Eur J Gastroenterol Hepatol 8 1996 905 909
23. M. Campieri, A. Ferguson, W. Doe, T. Persson, L.G. Nilsson Oral budesonide is as effective as oral prednisolone in active Crohn's disease The Global Budesonide Study Group Gut 41 1997 209 214
24. S.V. Kane, P. Schoenfeld, W.J. Sandborn, W. Tremaine, T. Hofer, B.G. Feagan The effectiveness of budesonide therapy for Crohn's disease Aliment Pharmacol Ther 16 2002 1509 1517
25. J.K. Marshall, E.J. Irvine Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis Gut 40 1997 775 781
26. R.D. Cohen, D.M. Woseth, R.A. Thisted, S.B. Hanauer A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis Am J Gastroenterol 95 2000 1263 1276
27. C.J. Mulder, P. Fockens, J.W. Meijer, H. van der Heide, E.H. Wiltink, G.N. Tytgat Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis Eur J Gastroenterol Hepatol 8 1996 549 553
28. K.W. Somerville, M.J. Langman, S.P. Kane, A.J. MacGilchrist, G. Watkinson, P. Salmon Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas Br Med J (Clin Res Ed) 291 1985 866
29. D.L. Braverman, E.A. Lachmann, W. Nagler Avascular necrosis of bilateral knees secondary to corticosteroid enemas Arch Phys Med Rehabil 79 1998 449 452
30. A. Danielsson, G. Hellers, E. Lyrenas, R. Lofberg, A. Nilsson, O. Olsson, S.A. Olsson, T. Persson, L. Salde, J. Naesdal A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis Scand J Gastroenterol 22 1987 987 992
31. The Danish Budesonide Study Group Budesonide enema in distal ulcerative colitis A randomized dose-response trial with prednisolone enema as positive control Scand J Gastroenterol 26 1991 1225 1230
32. R. Lofberg, O. Ostergaard Thomsen, E. Langholz, E. Langholz, R. Schioler, A. Danielsson, O. Suhr, H. Graffner, L. Pahlman, P. Matzen, J.F. Moller-Petersen Budesonide versus prednisolone retention enemas in active distal ulcerative colitis Aliment Pharmacol Ther 8 1994 623 629
33. M. Lemann, A. Galian, P. Rutgeerts, R. Van Heuverzwijn, A. Cortot, J.M. Viteau, A. Elewaut, J. Belaiche, E. Froguel, R. Modigliani Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis Aliment Pharmacol Ther 9 1995 557 562
34. G. Bianchi Porro, C. Prantera, M. Campieri Comparative trial of methylprednisolone and budesonide enemas in inactive distal ulcerative colitis Eur J Gastroenterol Hepatol 6 1994 125 130
35. S. Bar-Meir, H.H. Fidder, M. Faszczyk, G. Bianchi Porro, G.C. Sturniolo, O. Mickisch, R. Muller, R. Greinwald, Y. Chowers, V. Grobeta International Budesonide Study Group Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis Dis Colon Rectum 46 2003 929 936
36. R.W. Summers, D.M. Switz, J.T. Sessions Jr, J.M. Becktel, W.R. Best, F. Kern Jr, J.W. Singleton National Cooperative Crohn's Disease Study: results of drug treatment Gastroenterology 77 1979 847 869
37. H. Malchow, K. Ewe, J.W. Brandes, H. Goebell, H. Ehms, H. Sommer, H. Jesdinsky European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment Gastroenterology 86 1984 249 266
38. R. Modigliani, J.Y. Mary, J.F. Simon, A. Cortot, J.C. Soule, J.P. Gendre, E. Rene Clinical, biological, and endoscopic picture of attacks of Crohn's disease Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives Gastroenterology 98 1990 811 818
39. J.A. Shaffer, S.E. Williams, L.A. Turnberg, J.B. Houston, M. Rowland Absorption of prednisolone in patients with Crohn's disease Gut 24 1983 182 186
40. W.A. Faubion Jr, E.V. Loftus Jr, W.S. Harmsen, A.R. Zinsmeister, W.J. Sandborn The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 121 2001 255 260
41. P. Munkholm, E. Langholz, M. Davidsen, V. Binder Frequency of glucocorticoid resistance and dependency in Crohn's disease Gut 35 1994 360 362
42. S.C. Truelove, L.J. Witts Cortisone in ulcerative colitis; preliminary report on a therapeutic trial Br Med J 4884 1954 375 378
43. S.C. Truelove, L.J. Witts Cortisone in ulcerative colitis; final report on a therapeutic trial Br Med J 4947 1955 1041 1048
44. S.C. Truelove, G. Watkinson, G. Draper Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis Br Med J 5321 1962 1708 1711
45. P.A. Van Hees, H.J. Van Lier, P.H. Van Elteren, M. Driessen, R.A. Van Hogezand, G.P. Ten Velde, J.H. Bakker, J.H. Van Tongeren Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study Gut 22 1981 404 409
46. S.C. Truelove, C.P. Willoughby, E.G. Lee, M.G. Kettlewell Further experience in the treatment of severe attacks of ulcerative colitis Lancet 2 1978 1086 1088
47. S.C. Truelove, D.P. Jewell Intensive intravenous regimen for severe attacks of ulcerative colitis Lancet 1 1974 1067 1070
48. S. Meyers, D.B. Sachar, J.D. Goldberg, H.D. Janowitz Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis A prospective, randomized, double-blind clinical trial Gastroenterology 85 1983 351 357
49. J. Powell-Tuck, N.A. Buckell, J.E. Lennard-Jones A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis Scand J Gastroenterol 12 1977 971 975
50. H.P. Kaplan, B. Portnoy, H.J. Binder, T. Amatruda, H. Spiro A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis Gastroenterology 69 1975 91 95
51. G. Jarnerot, P. Rolny, H. Sandberg-Gertzen Intensive intravenous treatment of ulcerative colitis Gastroenterology 89 1985 1005 1013
52. H.A. Shepherd, G.D. Barr, D.P. Jewell Use of an intravenous steroid regimen in the treatment of acute Crohn's disease J Clin Gastroenterol 8 1986 154 159
53. A. Chun, R.M. Chadi, B.I. Korelitz, T. Colonna, J.B. Felder, M.H. Jackson, E.H. Morgenstern, S.D. Rubin, A.G. Sacknoff, G.M. Gleim Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up Inflamm Bowel Dis 4 1998 177 181
54. S.C. Truelove, L.J. Witts Cortisone and corticotrophin in ulcerative colitis Br Med J 34 1959 387 394
55. J.E. Lennard-Jones, J.J. Mickiewicz, A.M. Connell, J.H. Baron, F.A. Jones Prednisone as maintenance treatment for ulcerative colitis in remission Lancet 191 1965 188 189
56. J. Powell-Tuck, R.L. Bown, T.J. Chambers, J.E. Lennard-Jones A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission Digestion 22 1981 263 270
57. G.R. Greenberg, B.G. Feagan, F. Martin, L.R. Sutherland, A.B. Thomson, C.N. Williams, L.G. Nilsson, T. Persson Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study Canadian Inflammatory Bowel Disease Study Group Gastroenterology 110 1996 45 51
58. R. Lofberg, P. Rutgeerts, H. Malchow, C. Lamers, A. Danielsson, G. Olaison, D. Jewell, O. Ostergaard Thomsen, H. Lorenz-Meyer, H. Goebell, H. Hodgson, T. Persson, C. Seidegard Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease A placebo controlled one year study Gut 39 1996 82 86
59. A. Ferguson, M. Campieri, W. Doe, T. Persson, G. Nygard Oral budesonide as maintenance therapy in Crohn's disease - results of a 12-month study Global Budesonide Study Group Aliment Pharmacol Ther 12 1998 175 183
60. V. Gross, T. Andus, K.W. Ecker, A. Raedler, K. Loeschke, M. Plauth, J. Rasenack, A. Weber, M. Gierend, K. Ewe, J. Scholmerich Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease The Budesonide Study Group Gut 42 1998 493 496
61. S. Hanauer, W.J. Sandborn, A. Persson, T. Persson Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial Aliment Pharmacol Ther 21 2005 363 371
62. W.J. Sandborn, R. Lofberg, B.G. Feagan, S.B. Hanauer, M. Campieri, G.R. Greenberg Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials Am J Gastroenterol 100 2005 1780 1787
63. K. Ewe, T. Bottger, H.J. Buhr, K.W. Ecker, H.F. Otto Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial German Budesonide Study Group Eur J Gastroenterol Hepatol 11 1999 277 282
64. G. Hellers, A. Cortot, D. Jewell, C.E. Leijonmarck, R. Lofberg, H. Malchow, L.G. Nilsson, F. Pallone, S. Pena, T. Persson, C. Prantera, P. Rutgeerts Oral budesonide for prevention of postsurgical recurrence in Crohn's disease The IOIBD Budesonide Study Group Gastroenterology 116 1999 294 300
65. G. Mantzaris, K. Petraki, H. Chadio-Iordanides Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease (abstr) Gastroenterology 122 2002 A-81
66. J.H. Baron, A.M. Connell, T.G. Kanaghinis, J.E. Lennard-Jones, A.F. Jones Out-patient treatment of ulcerative colitis Comparison between three doses of oral prednisone Br Med J 5302 1962 441 443
67. J. Powell-Tuck, R.L. Bown, J.E. Lennard-Jones A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis Scand J Gastroenterol 13 1978 833 837
68. L.M. Berghouse, P.R. Elliott, J.E. Lennard-Jones, J. English, V. Marks Plasma prednisolone levels during intravenous therapy in acute colitis Gut 23 1982 980 983
69. B. Landi, T.N. Anh, A. Cortot, J.C. Soule, E. Rene, J.P. Gendre, P. Bories, A. See, E.H. Metman, C. Florent Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives Gastroenterology 102 1992 1647 1653
70. R. Modigliani, J.F. Colombel, J.L. Dupas, M. Dapoigny, V. Costil, M. Veyrac, B. Duclos, J.C. Soule, J.P. Gendre, J.P. Galmiche, O. Danne, G. Cadiot, H. Lamouliatte, J. Belaiche, J.Y. Mary Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives Gastroenterology 110 1996 688 693
71. C. Brignola, G. De Simone, P. Iannone, C. Belloli, A. Evangelisti, M. Campieri, A. Belluzzi, P. Gionchetti, M. Tampieri, E. Bertinelli Influence of steroid treatment's duration in patients with active Crohn's disease. gents Actions 1992 C90 C92 Spec
72. A. Cortot, J.F. Colombel, P. Rutgeerts, K. Lauritsen, H. Malchow, J. Hamling, T. Winter, A. Van Gossum, T. Persson, E. Pettersson Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease Gut 48 2001 186 190
73. J.W. Singleton, D.H. Law, M.L. Kelley Jr, H.S. Mekhjian, R.A. Sturdevant National Cooperative Crohn's Disease Study: adverse reactions to study drugs Gastroenterology 77 1979 870 882
74. F.N. Aberra, J.D. Lewis, D. Hass, J.L. Rombeau, B. Osborne, G.R. Lichtenstein Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients Gastroenterology 125 2003 320 327
75. C.N. Bernstein, W.D. Leslie, M.S. Leboff AGA technical review on osteoporosis in gastrointestinal diseases Gastroenterology 124 2003 795 841
76. K.V. Haderslev, L. Tjellesen, H.A. Sorensen, M. Staun Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease Gastroenterology 119 2000 639 646
77. D. Clements, J.E. Compston, W.D. Evans, J. Rhodes Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease Gut 34 1993 1543 1546
78. Y.X. Yang, G.R. Lichtenstein Corticosteroids in Crohn's disease Am J Gastroenterol 97 2002 803 823
79. Y.F. Liu, W.M. Chen, Y.F. Lin, R.C. Yang, M.W. Lin, L.H. Li, Y.H. Chang, Y.S. Jou, P.Y. Lin, J.S. Su, S.F. Huang, K.J. Hsiao, C.S. Fann, H.W. Hwang, Y.T. Chen, S.F. Tsai Type II collagen gene variants and inherited osteonecrosis of the femoral head N Engl J Med 352 2005 2294 2301
80. E.J. Schoon, S. Bollani, P.R. Mills, E. Israeli, D. Felsenberg, S. Ljunghall, T. Persson, L. Hapten-White, H. Graffner, G. Bianchi Porro, M. Vatn, R.W. Stockbrugger Matrix Study Group Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease Clin Gastroenterol Hepatol 3 2005 113 121
81. M.S. Cooper, P.M. Stewart Corticosteroid insufficiency in acutely ill patients N Engl J Med 348 2003 727 734
82. G.R. Lichtenstein Use of laboratory testing to guide 6-mercaptopurine/ azathioprine therapy Gastroenterology 127 2004 1558 1564
83. L. Lennard The clinical pharmacology of 6-mercaptopurine Eur J Clin Pharmacol 43 1992 329 339
84. M.C. Dubinsky, S. Lamothe, H.Y. Yang, S.R. Targan, D. Sinnett, Y. Theoret, E.G. Seidman Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 2000 705 713
85. C. Cuffari, S. Hunt, T. Bayless Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease Gut 48 2001 642 646
86. P.W. Lowry, C.L. Franklin, A.L. Weaver, M.G. Pike, D.C. Mays, W.J. Tremaine, J.J. Lipsky, W.J. Sandborn Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease Gut 49 2001 665 670
87. P. Gupta, R. Gokhale, B.S. Kirschner 6-mercaptopurine metabolite levels in children with inflammatory bowel disease J Pediatr Gastroenterol Nutr 33 2001 450 454
88. F.N. Aberra, G.R. Lichtenstein Review article: monitoring of immunomodulators in inflammatory bowel disease Aliment Pharmacol Ther 21 2005 307 319
89. M.C. Dubinsky, H. Yang, P.V. Hassard, E.G. Seidman, L.Y. Kam, M.T. Abreu, S.R. Targan, E.A. Vasiliauskas 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease Gastroenterology 122 2002 904 915
90. R.M. Weinshilboum, S.L. Sladek Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity Am J Hum Genet 32 1980 651 662
91. J.F. Colombel, N. Ferrari, H. Debuysere, P. Marteau, J.P. Gendre, B. Bonaz, J.C. Soule, R. Modigliani, Y. Touze, P. Catala, C. Libersa, F. Broly Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy Gastroenterology 118 2000 1025 1030
92. Package insert for azathioprine/6-mercaptopurine. Imuran®, Prometheus Laboratories, Inc., San Diego, California, 2005.
93. W.R. Connell, M.A. Kamm, M. Dickson, A.M. Balkwill, J.K. Ritchie, J.E. Lennard-Jones Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease Lancet 343 1994 1249 1252
94. D.H. Present, S.J. Meltzer, M.P. Krumholz, A. Wolke, B.I. Korelitz 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity Ann Intern Med 111 1989 641 649
95. W.J. Sandborn A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate Am J Gastroenterol 91 1996 423 433
96. C.J. Haber, S.J. Meltzer, D.H. Present, B.I. Korelitz Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease Gastroenterology 91 1986 982 986
97. B.I. Korelitz, J. Zlatanic, F. Goel, S. Fuller Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease J Clin Gastroenterol 28 1999 341 344
98. B. Cheng, G. Lichtenstein Are individuals with Crohn's disease who are intolerant to 6-mercaptopurine able to tolerate azathioprine? (abstr) Gastroenterology 118 2000 A1336
99. J.R. Boulton-Jones, K. Pritchard, A.A. Mahmoud The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy Aliment Pharmacol Ther 14 2000 1561 1565
100. J. George, D.H. Present, R. Pou, C. Bodian, P.H. Rubin The long-term outcome of ulcerative colitis treated with 6-mercaptopurine Am J Gastroenterol 91 1996 1711 1714
101. B.I. Korelitz, S.R. Fuller, J.I. Warman, M.D. Goldberg Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease Am J Gastroenterol 94 1999 424 426
102. P. Pfau, M.L. Kochman, E.E. Furth, G.R. Lichtenstein Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient Am J Gastroenterol 96 2001 895 899
103. D.C. Pearson, G.R. May, G.H. Fick, L.R. Sutherland Azathioprine and 6-mercaptopurine in Crohn disease A meta-analysis Ann Intern Med 123 1995 132 142
104. P.W. Lowry, C.L. Franklin, A.L. Weaver, C.L. Szumlanski, D.C. Mays, E.V. Loftus, W.J. Tremaine, J.J. Lipsky, R.M. Weinshilboum, W.J. Sandborn Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide Gut 49 2001 656 664
105. C.L. Szumlanski, R.M. Weinshilboum Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine Br J Clin Pharmacol 39 1995 456 459
106. L.D. Lewis, A. Benin, D.M. Szumlanski CL Otterness, L. Lennard, R.M. Weinshilboum, D.W. Nierenberg Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction Clin Pharmacol Ther 62 1997 464 475
107. S. Gardiner, E. Begg, M. Barclay, C. Kirkpatrick Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine Adverse Drug React Toxicol Rev 19 2000 293 312
108. M.A. Peppercorn 6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come Am J Gastroenterol 91 1996 1689 1690
109. J.D. Lewis, J.S. Schwartz, G.R. Lichtenstein Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma Gastroenterology 118 2000 1018 1024
110. A. Kandiel, A.G. Fraser, B.I. Korelitz, C. Brensinger, J.D. Lewis Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine Gut 54 2005 1121 1125
111. J. Winter, A. Walker, D. Shapiro, D. Gaffney, R.J. Spooner, P.R. Mills Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease Aliment Pharmacol Ther 20 2004 593 599
112. A.J. Black, H.L. McLeod, H.A. Capell, R.H. Powrie, L.K. Matowe, S.C. Pritchard, E.S. Collie-Duguid, D.M. Reid Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine Ann Intern Med 129 1998 716 718
113. M. Seddik, F. Texier, N. Ferrari Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's disease (abstr) Gastroenterology 124 2003 A311
114. W. Curvers, L. Derijks, P. Stokkers No predictive value of TPMT genotyping for leukopenia or hepatotoxicity during azathioprine therapy for inflammatory bowel disease (abstr) Gastroenterology 124 2003 A377
115. L. Sebbag, P. Boucher, P. Davelu, P. Boissonnat, G. Champsaur, J. Ninet, G. Dureau, J.F. Obadia, J.J. Vallon, J. Delaye Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients Transplantation 69 2000 1524 1527
116. B.A. Kaskas, E. Louis, U. Hindorf, E. Schaeffeler, J. Deflandre, F. Graepler, K. Schmiegelow, M. Gregor, U.M. Zanger, M. Eichelbaum, M. Schwab Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine Gut 52 2003 140 142
117. C. Su, G.R. Lichtenstein Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine Gastroenterol Clin North Am 33 2004 209 234 viii
118. B.N. Brooke, D.C. Hoffmann, E.T. Swarbrick Azathioprine for Crohn's disease Lancet 2 1969 612 614
119. J. Rhodes, D. Bainton, P. Beck, H. Campbell Controlled trial of azathioprine in Crohn's disease Lancet 2 1971 1273 1276
120. J.M. Willoughby, J. Beckett, P.J. Kumar, A.M. Dawson Controlled trial of azathioprine in Crohn's disease Lancet 2 1971 944 947
121. M. Klein, H.J. Binder, M. Mitchell, R. Aaronson, H. Spiro Treatment of Crohn's disease with azathioprine: a controlled evaluation Gastroenterology 66 1974 916 922
122. D.H. Present, B.I. Korelitz, N. Wisch, J.L. Glass, D.B. Sachar, B.S. Pasternack Treatment of Crohn's disease with 6-mercaptopurine A long-term, randomized, double-blind study N Engl J Med 302 1980 981 987
123. K. Ewe, A.G. Press, C.C. Singe, M. Stufler, B. Ueberschaer, G. Hommel, K.H. Meyer zum Buschenfelde Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease Gastroenterology 105 1993 367 372
124. S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig, R. Goodman A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
125. R. Oren, M. Moshkowitz, S. Odes, S. Becker, D. Keter, I. Pomeranz, C. Shirin, I. Reisfeld, E. Broide, A. Lavy, A. Fich, R. Eliakim, J. Patz, Y. Villa, N. Arber, T. Gilat Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial Am J Gastroenterol 92 1997 2203 2209
126. A.B. Hawthorne, R.F. Logan, C.J. Hawkey, P.N. Foster, A.T. Axon, E.T. Swarbrick, B.B. Scott, J.E. Lennard-Jones Randomised controlled trial of azathioprine withdrawal in ulcerative colitis BMJ 305 1992 20 22
127. D.P. Jewell, S.C. Truelove Azathioprine in ulcerative colitis: final report on controlled therapeutic trial Br Med J 4 1974 627 630
128. J.L. Rosenberg, A.J. Wall, B. Levin, H.J. Binder, J.B. Kirsner A controlled trial of azathioprine in the management of chronic ulcerative colitis Gastroenterology 69 1975 96 99
129. A.P. Kirk, J.E. Lennard-Jones Controlled trial of azathioprine in chronic ulcerative colitis Br Med J (Clin Res Ed) 284 1982 1291 1292
130. R. Caprilli, R. Carratu, M. Babbini Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis Preliminary report Am J Dig Dis 20 1975 115 120
131. S. Ardizzone, F. Samolvico, S. Bollani, V. Imbesi, E. Colombo, G. Bianchi Porro Azathioprine is more effective than oral 5-ASA in the treatment of steroid-dependent ulcerative colitis (abstr) Gastroenterology 120 2001 A127
132. G.J. Mantzaris, M. Sfakianakis, E. Archavlis, K. Petraki, A. Christidou, A. Karagiannidis, G. Triadaphyllou A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis Am J Gastroenterol 99 2004 1122 1128
133. A. Sood, V. Midha, N. Sood, V. Kaushal Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial Indian J Gastroenterol 19 2000 14 16
134. R.D. Cohen, R. Stein, S.B. Hanauer Intravenous cyclosporin in ulcerative colitis: a five-year experience Am J Gastroenterol 94 1999 1587 1592
135. F. Fernandez-Banares, X. Bertran, M. Esteve-Comas, E. Cabre, M. Menacho, P. Humbert, R. Planas, M.A. Gassull Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis Am J Gastroenterol 91 1996 2498 2499
136. E. Domenech, E. Garcia-Planella, I. Bernal, M. Rosinach, E. Cabre, L. Fluvia, J. Boix, M.A. Gassull Azathioprine without oral cyclosporin in the long-term maintenance of remission induced by intravenous cyclosporin in severe, steroid-refractory ulcerative colitis Aliment Pharmacol Ther 16 2002 2061 2065
137. J. Markowitz, K. Grancher, N. Kohn, M. Lesser, F. Daum A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease Gastroenterology 119 2000 895 902
138. J.L. Rosenberg, B. Levin, A.J. Wall, J.B. Kirsner A controlled trial of azathioprine in Crohn's disease Am J Dig Dis 20 1975 721 726
139. D.P. O'Donoghue, A.M. Dawson, J. Powell-Tuck, R.L. Brown, J.E. Lennard-Jones Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease Lancet 2 1978 955 957
140. J.P. Achkar, S.B. Hanauer Medical therapy to reduce postoperative Crohn's disease recurrence Am J Gastroenterol 95 2000 1139 1146
141. G. Olaison, K. Smedh, R. Sjodahl Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms Gut 33 1992 331 335
142. P. Rutgeerts, K. Geboes, G. Vantrappen, J. Beyls, R. Kerremans, M. Hiele Predictability of the postoperative course of Crohn's disease Gastroenterology 99 1990 956 963
143. E. Lautenbach, J.A. Berlin, G.R. Lichtenstein Risk factors for early postoperative recurrence of Crohn's disease Gastroenterology 115 1998 259 267
144. P. Rutgeerts, M. Hiele, K. Geboes, M. Peeters, F. Penninckx, R. Aerts, R. Kerremans Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection Gastroenterology 108 1995 1617 1621
145. P. Rutgeerts, G. Van Assche, S. Vermeire, G. D'Haens, F. Baert, M. Noman, I. Aerden, G. De Hertogh, K. Geboes, M. Hiele, A. D'Hoore, F. Penninckx Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial Gastroenterology 128 2005 856 861
146. S.B. Hanauer, B.I. Korelitz, P. Rutgeerts, M.A. Peppercorn, R.A. Thisted, R.D. Cohen, D.H. Present Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial Gastroenterology 127 2004 723 729
147. W.J. Sandborn, B.G. Feagan The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain Gastroenterology 127 2004 990 993
148. S. Ardizzone, G. Maconi, G.M. Sampietro, A. Russo, E. Radice, E. Colombo, V. Imbesi, M. Molteni, P.G. Danelli, A.M. Taschieri, G. Bianchi Porro Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease Gastroenterology 127 2004 730 740
149. S. Hanauer, R. Cohen, R. Thisted, P. Rutgeerts, D. Present, B. Korelitz Reply to: 6-mercaptopurine and mesalamine for prevention of relapse after conservative therapy for Crohn's disease (letter) Gastroenterology 128 2005 249 251
150. B.G. Feagan, J. Rochon, R.N. Fedorak, J.E. Irvine, G. Wild, L. Sutherland, A.H. Steinhart, G.R. Greenberg, R. Gillies, M. Hopkins, S.B. Hanauer, J.W.D. McDonald Methotrexate for the treatment of Crohn's disease The North American Crohn's Study Group Investigators N Engl J Med 332 1995 292 297
151. R. Oren, N. Arber, S. Odes, M. Moshkowitz, D. Keter, I. Pomeranz, Y. Ron, I. Reisfeld, E. Broide, A. Lavy, A. Fich, R. Eliakim, J. Patz, E. Bardan, Y. Villa, T. Gilat Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial Gastroenterology 110 1996 1416 1421
152. S. Arora, W. Katkov, J. Cooley, J.A. Kemp, D.E. Johnston, R.H. Schapiro, D. Podolsky Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial Hepatogastroenterology 46 1999 1724 1729
153. B.G. Feagan, R.N. Fedorak, E.J. Irvine, L. Sutherland, A.H. Steinhart, G.R. Greenberg, J. Koval, C.J. Wong, M. Hopkins, S.B. Hanauer, J.W. McDonald A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease North American Crohn's Study Group Investigators N Engl J Med 342 2000 1627 1632
154. R.Y. Chong, S.B. Hanauer, R.D. Cohen Efficacy of parenteral methotrexate
155. G. Fraser, O. Ben-Bassat, N. Segal, M. Fishman-Mor, Y. Niv Parenteral methotrexate is not effective treatment for refractory ulcerative colitis Gastroenterology 124 Suppl 1 2003 A525
156. J.R. Cummings, K.R. Herrlinger, S.P. Travis, D.A. Gorard, A.S. McIntyre, D.P. Jewell Oral methotrexate in ulcerative colitis Aliment Pharmacol Ther 21 2005 385 389
157. U. Mahadevan, J.F. Marion, D.H. Present Fistula response to methotrexate in Crohn's disease: a case series Aliment Pharmacol Ther 18 2003 1003 1008
158. L. Vandeputte, G. D'Haens, F. Baert, P. Rutgeerts Methotrexate in refractory Crohn's disease Inflamm Bowel Dis 5 1999 11 15
159. M.S. Campbell, K.R. Reddy Review article: the evolving role of liver biopsy Aliment Pharmacol Ther 20 2004 249 259
160. R. Kozarek, J. Brefeldt, L. Rosoff, D. Patterson, L. Fenster Does methotrexate (MTX) cause liver toxicity when used for refractory inflammatory bowel disease (IBD)? (abstr) Gastroenterology 100 1991 A221
161. H.S. Te, T.D. Schiano, S.F. Kuan, S.B. Hanauer, H.S. Conjeevaram, A.L. Baker Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease Am J Gastroenterol 95 2000 3150 3156
162. J.M. Kremer, G.S. Alarcon, R.W. Lightfoot Jr, R.F. Willkens, D.E. Furst, H.J. Williams, P.B. Dent, M.E. Weinblatt Methotrexate for rheumatoid arthritis Suggested guidelines for monitoring liver toxicity. American College of Rheumatology Arthritis Rheum 37 1994 316 328
163. J.M. Kremer, J. Galivan, A. Streckfuss, B. Kamen Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients Association with hepatic folate deficiency and formation of polyglutamates Arthritis Rheum 29 1986 832 835
164. R.L. Schilsky, B.J. Lewis, R.J. Sherins, R.C. Young Gonadal dysfunction in patients receiving chemotherapy for cancer Ann Intern Med 93 1980 109 114
165. G.J. Rustin, M. Booth, J. Dent, S. Salt, F. Rustin, K.D. Bagshawe Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours Br Med J (Clin Res Ed) 288 1984 103 106
166. L. Weissbach, C.E. Lange, O.E. Rodermund, H. Zwicker, A. Gropp, W. Pothmann [Fertility disturbances following treatment of patients with testicular tumors (author's transl)] Urologe A 13 1974 80 85
167. E. Hinkes, D. Plotkin Reversible drug-induced sterility in a patient with acute leukemia JAMA 223 1973 1490 1491
168. A. Sussman, J.M. Leonard Psoriasis, methotrexate, and oligospermia Arch Dermatol 116 1980 215 217
169. A. Milunsky, J.W. Graef, M.F. Gaynor Jr Methotrexate-induced congenital malformations J Pediatr 72 1968 790 795
170. H.R. Powell, H. Ekert Methotrexate-induced congenital malformations Med J Aust 2 1971 1076 1077
171. J. Pizzuto, A. Aviles, L. Noriega, J. Niz, M. Morales, F. Romero Treatment of acute leukemia during pregnancy: presentation of nine cases Cancer Treat Rep 64 1980 679 683
172. D.B. Okun, P.K. Groncy, L. Sieger, K.R. Tanaka Acute leukemia in pregnancy: transient neonatal myelosuppression after combination chemotherapy in the mother Med Pediatr Oncol 7 1979 315 319
173. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation. 5th ed. Baltimore, MD: Williams and Wilkins, 1998.
174. American Academy of Pediatrics Committee on Drugs The transfer of drugs and other chemicals into human milk Pediatrics 93 1994 137 150
175. J.E. Kitchin, M.K. Pomeranz, G. Pak, K. Washenik, J.L. Shupack Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses J Am Acad Dermatol 37 1997 445 449
176. P. Fickert, T.A. Hinterleitner, H.H. Wenzl, B.W. Aichbichler, W. Petritsch Mycophenolate mofetil in patients with Crohn's disease Am J Gastroenterol 93 1998 2529 2532
177. M.F. Neurath, R. Wanitschke, M. Peters, F. Krummenauer, K.H. Meyer zum Buschenfelde, J.F. Schlaak Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease Gut 44 1999 625 628
178. T. Orth, M. Peters, J.F. Schlaak, F. Krummenauer, R. Wanitschke, W.J. Mayet, P.R. Galle, M.F. Neurath Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study Am J Gastroenterol 95 2000 1201 1207
179. P.V. Hassard, E.A. Vasiliauskas, L.Y. Kam, S.R. Targan, M.T. Abreu Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease Inflamm Bowel Dis 6 2000 16 20
180. K. Fellermann, M. Steffen, J. Stein, A. Raedler, J. Hamling, D. Ludwig, K. Loeschke, E.F. Stange Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease Aliment Pharmacol Ther 14 2000 171 176
181. W. Miehsler, W. Reinisch, G. Moser, A. Gangl, H. Vogelsang Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 96 2001 782 787
182. S. Hafraoui, O. Dewit, P. Marteau, J. Cosnes, J.F. Colombel, R. Modigliani, A. Cortot, M. Lemann [Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate ] Gastroenterol Clin Biol 26 2002 17 22
183. M.M. Skelly, R.F. Logan, D. Jenkins, Y.R. Mahida, C.J. Hawkey Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease Inflamm Bowel Dis 8 2002 93 97
184. J.C. Papadimitriou, C.B. Cangro, A. Lustberg, A. Khaled, J. Nogueira, A. Wiland, E. Ramos, D.K. Klassen, C.B. Drachenberg Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern Int J Surg Pathol 11 2003 295 302
185. I.J. Dalle, B.D. Maes, K.P. Geboes, W. Lemahieu, K. Geboes Crohn's-like changes in the colon due to mycophenolate? Colorectal Dis 7 2005 27 34
186. J.F. Borel, C. Feurer, H.U. Gubler, H. Stahelin Biological effects of cyclosporin A: a new antilymphocytic agent Agents Actions 6 1976 468 475
187. J. Liu, J.D. Farmer Jr, W.S. Lane, J. Friedman, I. Weissman, S.L. Schreiber Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell 66 1991 807 815
188. S.L. Schreiber, G.R. Crabtree The mechanism of action of cyclosporin A and FK506 Immunol Today 13 1992 136 142
189. S. Gupta, A. Keshavarzian, H.J. Hodgson Cyclosporin in ulcerative colitis Lancet 2 1984 1277 1278
190. J.S. Hyams, W.R. Treem Cyclosporine treatment of fulminant colitis J Pediatr Gastroenterol Nutr 9 1989 383 387
191. S. Lichtiger, D.H. Present Preliminary report: cyclosporin in treatment of severe active ulcerative colitis Lancet 336 1990 16 19
192. G.B. Porro, M. Petrillo, S. Ardizzone Cyclosporin treatment for severe active ulcerative colitis Lancet 336 1990 439
193. S. Lichtiger, D.H. Present, A. Kornbluth, I. Gelernt, J. Bauer, G. Galler, F. Michelassi, S. Hanauer Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841 1845
194. J. Santos, S. Baudet, F. Casellas, L. Guarner, J. Vilaseca, J.R. Malagelada Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis J Clin Gastroenterol 20 1995 285 289
195. W.R. Treem, J. Cohen, P.M. Davis, C.J. Justinich, J.S. Hyams Cyclosporine for the treatment of fulminant ulcerative colitis in children Immediate response, long-term results, and impact on surgery Dis Colon Rectum 38 1995 474 479
196. A. Kornbluth, S. Lichtiger, D. Present, S. Hanauer Long-term results of oral cyclosporine in patients with severe ulcerative colitis: a double-blind, randomized, multi-center trial (abstr) Gastroenterology 106 1994 A714
197. F. Carbonnel, A. Boruchowicz, B. Duclos, J.C. Soule, E. Lerebours, M. Lemann, J. Belaiche, J.F. Colombel, J. Cosnes, J.P. Gendre Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses Dig Dis Sci 41 1996 2471 2476
198. A. Van Gossum, A. Schmit, M. Adler, C. Chioccioli, R. Fiasse, P. Louwagie, G. D'Haens, P. Rutgeerts, M. De Vos, H. Reynaert, G. Devis, J. Belaiche, M. Van Outryve Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis Belgian IBD Group Acta Gastroenterol Belg 60 1997 197 200
199. A. Kornbluth, D.H. Present, S. Lichtiger, S. Hanauer Cyclosporin for severe ulcerative colitis: a user's guide Am J Gastroenterol 92 1997 1424 1428
200. A. Kornbluth, D.B. Sachar Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee Am J Gastroenterol 99 2004 1371 1385
201. M.B. Smith, S.B. Hanauer Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis N Engl J Med 327 1992 497 498
202. W. Sandborn A critical review of cyclosporine therapy in inflammatory bowel disease Inflamm Bowel Dis 1 1995 48 63
203. E. Schutz, D. Svinarov, M. Shipkova, P.D. Niedmann, V.W. Armstrong, E. Wieland, M. Oellerich Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC Clin Chem 44 1998 2158 2164
204. S. Vermeire, P. Rutgeerts Cyclosporine monotherapy is effective in the treatment of severe ulcerative colitis Inflamm Bowel Dis 2 1996 253 254
205. G. D'Haens, L. Lemmens, K. Geboes, L. Vandeputte, F. Van Acker, L. Mortelmans, M. Peeters, S. Vermeire, F. Penninckx, F. Nevens, M. Hiele, P. Rutgeerts Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis Gastroenterology 120 2001 1323 1329
206. R.D. Cohen Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? Gastroenterology 120 2001 1541 1543
207. G. Van Assche, G. D'Haens, M. Noman, S. Vermeire, M. Hiele, K. Asnong, J. Arts, A. D'Hoore, F. Penninckx, P. Rutgeerts Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis Gastroenterology 125 2003 1025 1031
208. B.F. Allam, J.E. Tillman, T.J. Thomson, F.T. Crossling, L.M. Gilbert Effective intravenous cyclosporin therapy in a patient with severe Crohn's disease on parenteral nutrition Gut 28 1987 1166 1169
209. A.J. Lobo, L.D. Juby, J. Rothwell, T.W. Poole, A.T. Axon Long-term treatment of Crohn's disease with cyclosporine: the effect of a very low dose on maintenance of remission J Clin Gastroenterol 13 1991 42 45
210. S. Lichtiger Cyclosporine therapy in inflammatory bowel disease: open-label experience Mt Sinai J Med 57 1990 315 319
211. G. Mahdi, D.M. Israel, E. Hassall Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children Am J Gastroenterol 91 1996 1355 1359
212. L.J. Egan, W.J. Sandborn, W.J. Tremaine Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine Am J Gastroenterol 93 1998 442 448
213. D.H. Present, S. Lichtiger Efficacy of cyclosporine in treatment of fistula of Crohn's disease Dig Dis Sci 39 1994 374 380
214. T.A. Hinterleitner, W. Petritsch, B. Aichbichler, P. Fickert, G. Ranner, G.J. Krejs Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease Z Gastroenterol 35 1997 603 608
215. T.A. Judge, G.R. Lichtenstein Treatment of fistulizing Crohn's disease Gastroenterol Clin North Am 33 2004 421 454 xi-xii
216. J. Drewe, R. Meier, J. Vonderscher, D. Kiss, U. Posanski, T. Kissel, K. Gyr Enhancement of the oral absorption of cyclosporin in man Br J Clin Pharmacol 34 1992 60 64
217. E.A. Mueller, J.M. Kovarik, J.B. van Bree, W. Tetzloff, J. Grevel, K. Kutz Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation Pharm Res 11 1994 301 304
218. J.M. Kovarik, E.A. Mueller, A. Johnston, G. Hitzenberger, K. Kutz Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation Pharmacotherapy 13 1993 613 617
219. U.A. Frei, H.H. Neumayer, B. Buchholz, D. Niese, E.A. Mueller Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients International Sandimmun Neoral Study Group Transplantation 65 1998 1455 1460
220. G.C. Actis, G. Aimo, G. Priolo, D. Moscato, M. Rizzetto, R. Pagni Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial Inflamm Bowel Dis 4 1998 276 279
221. G.C. Actis, R. Volpes, M. Rizzetto Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis Eur J Gastroenterol Hepatol 11 1999 905 908
222. L. Navazo, H. Salata, S. Morales, M.C. Dorta, F. Perez, D. de las Casas, J. Aviles Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis Scand J Gastroenterol 36 2001 610 614
223. J. Brynskov, L. Freund, S.N. Rasmussen, K. Lauritsen, O.S. de Muckadell, N. Williams, A.S. MacDonald, R. Tanton, F. Molina, M.C. Campanini A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease N Engl J Med 321 1989 845 850
224. J. Brynskov, L. Freund, S. Norby Rasmussen, S. Rasmussen, K. Lauritsen, O. Schaffalitzky de Muckadell, C.N. Williams, A.S. MacDonald, R. Tanton, F. Molina, M.C. Campanini Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease Scand J Gastroenterol 26 1991 689 695
225. D.P. Jewell, J.E. Lennard-Jones Oral cyclosporine for chronic active Crohn's disease: a multicentre controlled trial Eur J Gastroenterol Hepatol 6 1994 499 505
226. B.G. Feagan, J.W. McDonald, J. Rochon, A. Laupacis, R.N. Fedorak, D. Kinnear, F. Saibil, A. Groll, A. Archambault, R. Gillies, B. Valberg, E.J. Irvine Low-dose cyclosporine for the treatment of Crohn's disease The Canadian Crohn's Relapse Prevention Trial Investigators N Engl J Med 330 1994 1846 1851
227. E.F. Stange, R. Modigliani, A.S. Pena, A.J. Wood, G. Feutren, P.R. Smith European trial of cyclosporine in chronic active Crohn's disease: a 12-month study The European Study Group Gastroenterology 109 1995 774 782
228. B.G. Feagan, J.W. McDonald Cyclosporin in Crohn's disease Lancet 349 1997 1328
229. J.W. McDonald, B.G. Feagan, D. Jewell, J. Brynskov, E.F. Stange, J.K. Macdonald Cyclosporine for induction of remission in Crohn's disease Cochrane Database Syst Rev 2 2005 CD000297
230. J. Brynskov, L. Freund, O.O. Thomsen, C.B. Andersen, S.N. Rasmussen, V. Binder Treatment of refractory ulcerative colitis with cyclosporin enemas Lancet 1 1989 721 722
231. T. Ranzi, M.C. Campanini, P. Velio, F. Quarto di Palo, P. Bianchi Treatment of chronic proctosigmoiditis with cyclosporin enemas Lancet 2 1989 97
232. W.J. Sandborn, W.J. Tremaine, K.W. Schroeder, B.L. Steiner, K.P. Batts, G.M. Lawson Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis Am J Gastroenterol 88 1993 640 645
233. T.A. Winter, H.R. Dalton, M.N. Merrett, A. Campbell, D.P. Jewell Cyclosporin A retention enemas in refractory distal ulcerative colitis and "pouchitis." Scand J Gastroenterol 28 1993 701 704
234. W.J. Sandborn, W.J. Tremaine, K.W. Schroeder, K.P. Batts, G.M. Lawson, B.L. Steiner, J.M. Harrison, A.R. Zinsmeister A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis Gastroenterology 106 1994 1429 1435
235. W.M. Flanagan, B. Corthesy, R.J. Bram, G.R. Crabtree Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A Nature 352 1991 803 807
236. A. Bousvaros, B.S. Kirschner, S.L. Werlin, L. Parker-Hartigan, F. Daum, K.B. Freeman, J.P. Balint, A.S. Day, A.M. Griffiths, D. Zurakowski, G.D. Ferry, A.M. Leichtner Oral tacrolimus treatment of severe colitis in children J Pediatr 137 2000 794 799
237. K. Fellermann, Z. Tanko, K.R. Herrlinger, T. Witthoeft, N. Homann, A. Bruening, D. Ludwig, E.F. Stange Response of refractory colitis to intravenous or oral tacrolimus (FK506) Inflamm Bowel Dis 8 2002 317 324
238. C. Hogenauer, H.H. Wenzl, T.A. Hinterleitner, W. Petritsch Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis Aliment Pharmacol Ther 18 2003 415 423
239. P.W. Lowry, A.L. Weaver, W.J. Tremaine, W.J. Sandborn Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae Inflamm Bowel Dis 5 1999 239 245
240. E. Ierardi, M. Principi, M. Rendina, R. Francavilla, M. Ingrosso, A. Pisani, A. Amoruso, C. Panella, A. Francavilla Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum J Clin Gastroenterol 30 2000 200 202
241. W.J. Sandborn, D.H. Present, K.L. Isaacs, D.C. Wolf, E. Greenberg, S.B. Hanauer, B.G. Feagan, L. Mayer, T. Johnson, J. Galanko, C. Martin, R.S. Sandler Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial Gastroenterology 125 2003 380 388
242. S.J. Van Deventer Tumour necrosis factor and Crohn's disease Gut 40 1997 443 448
243. Physician's Desk Reference. 59th ed. Montvale, NJ: Medical Economics Co, 2005.
244. Physician's Desk Reference. 58th ed. Montvale, NJ: Medical Economics Co, 2004.
245. H.M. van Dullemen, S.J. van Deventer, D.W. Hommes, H.A. Bijl, J. Jansen, G.N. Tytgat, J. Woody Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109 1995 129 135
246. S.R. Targan, S.B. Hanauer, S.J. van Deventer, L. Mayer, D.H. Present, T. Braakman, K.L. DeWoody, T.F. Schaible, P.J. Rutgeerts A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease Crohn's Disease cA2 Study Group N Engl J Med 337 1997 1029 1035
247. P. Rutgeerts, G. D'Haens, S. Targan, E. Vasiliauskas, S.B. Hanauer, D.H. Present, L. Mayer, R.A. Van Hogezand, T. Braakman, K.L. DeWoody, T.F. Schaible, S.J. Van Deventer Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 1999 761 769
248. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, J.F. Colombel, D. Rachmilewitz, D.C. Wolf, A. Olson, W. Bao, P. Rutgeerts ACCENT I Study Group Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
249. P. Rutgeerts, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, J.F. Colombel, D. Rachmilewitz, D.C. Wolf, A. Olson, W. Bao, S.B. Hanauer Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Gastroenterology 126 2004 402 413
250. R.B. Sartor Episodic retreatment versus scheduled maintenance therapy of Crohn's disease with infliximab: not so far apart Gastroenterology 126 2004 598 601
251. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D' Haens, A. Carbonez, P. Rutgeerts Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 2003 601 608
252. S.B. Hanauer, C.L. Wagner, M. Bala, L. Mayer, S. Travers, R.H. Diamond, A. Olson, W. Bao, P. Rutgeerts Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease Clin Gastroenterol Hepatol 2 2004 542 553
253. R.J. Farrell, M. Alsahli, Y.T. Jeen, K.R. Falchuk, M.A. Peppercorn, P. Michetti Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial Gastroenterology 124 2003 917 924
254. W.J. Sandborn Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize Gastroenterology 124 2003 1140 1145
255. Lemann M, Colombel J, Duclos B, Veyrac M, Dupas J, Delchier J, Laharie D, Moreau J, Dadiot G, Sobhani I, Metman E, Boureille A. Infliximab in steroid dependent Crohn's Disease patients treated with azathioprine or 6-MP: a randomized double-blind placebo-controlled trial (abstr). Gut 203;52(Suppl):A44.
256. M.C. Hochberg, J.K. Tracy, M. Hawkins-Holt, R.H. Flores Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Ann Rheum Dis 62 Suppl 2 2003 13 16
257. D.H. Present, P. Rutgeerts, S. Targan, S.B. Hanauer, L. Mayer, R.A. van Hogezand, D.K. Podolsky, B.E. Sands, T. Braakman, K.L. DeWoody, T.F. Schaible, S.J. van Deventer Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
258. B.E. Sands, F.H. Anderson, C.N. Bernstein, W.Y. Chey, B.G. Feagan, R.N. Fedorak, M.A. Kamm, J.R. Korzenik, B.A. Lashner, J.E. Onken, D. Rachmilewitz, P. Rutgeerts, G. Wild, D.C. Wolf, P.A. Marsters, S.B. Travers, M.A. Blank, S.J. van Deventer Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 2004 876 885
259. A.A. van Bodegraven, C.E. Sloots, R.J. Felt-Bersma, S.G. Meuwissen Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response Dis Colon Rectum 45 2002 39 45 discussion 46
260. G. Van Assche, D. Vanbeckevoort, D. Bielen, G. Coremans, I. Aerden, M. Noman, A. D'Hoore, F. Penninckx, G. Marchal, F. Cornillie, P. Rutgeerts Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease Am J Gastroenterol 98 2003 332 339
261. L.S. Poritz, W.A. Rowe, W.A. Koltun Remicade does not abolish the need for surgery in fistulizing Crohn's disease Dis Colon Rectum 45 2002 771 775
262. B.E. Sands, M.A. Blank, K. Patel, S.J. van Deventer Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study Clin Gastroenterol Hepatol 2 2004 912 920
263. C. Levy, W.J. Tremaine Management of internal fistulas in Crohn's disease Inflamm Bowel Dis 8 2002 106 111
264. B.E. Sands, W.J. Tremaine, W.J. Sandborn, P.J. Rutgeerts, S.B. Hanauer, L. Mayer, S.R. Targan, D.K. Podolsky Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study Inflamm Bowel Dis 7 2001 83 88
265. P. Rutgeerts, B. Feagan, A. Olson, J. Johanns, S. Travers, D. Present, B.E. Sands, W. Sandborn, A. Olson A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial (abstr) Gastroenterology 128 2005 A689
266. W. Sandborn, D. Rachmilewitz, S. Hanauer, G.R. Lichtenstein, W.J. de Villiers, A. Olson, J. Johanns, S. Travers, J.-F. Colombel Infliximab induction and maintenance therapy for ulcerative colitis: the Act 2 trial (abstr) Gastroenterology 128 Suppl 2 2005 A688
267. G. Jarnerot, E. Hertervig, I. Friis-Liby, L. Blomquist, P. Karlen, C. Granno, M. Vilien, M. Strom, A. Danielsson, H. Verbaan, P.M. Hellstrom, A. Magnuson, B. Curman Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 128 2005 1805 1811
268. C.S. Probert, S.D. Hearing, S. Schreiber, T. Kuhbacher, S. Ghosh, I.D. Arnott, A. Forbes Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial Gut 52 2003 998 1002
269. P. Rutgeerts, W.J. Sandborn, B.G. Feagan, W. Reinisch, A. Olson, J. Johanns, S. Travers, D. Rachmilewitz, S.B. Hanauer, G.R. Lichtenstein, W.J.S. de Villiers, D. Present, B.E. Sands, J.F. Colombel Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
270. H. Herfarth, F. Obermeier, T. Andus, G. Rogler, S. Nikolaus, T. Kuehbacher, S. Schreiber Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease Am J Gastroenterol 97 2002 2688 2690
271. P. Rutgeerts, G. Van Assche, S. Vermeire Optimizing anti-TNF treatment in inflammatory bowel disease Gastroenterology 126 2004 1593 1610
272. V.L. Bowie, K.A. Snella, A.S. Gopalachar, P. Bharadwaj Listeria meningitis associated with infliximab Ann Pharmacother 38 2004 58 61
273. J.F. Colombel, E.V. Loftus Jr, W.J. Tremaine, L.J. Egan, W.S. Harmsen, C.D. Schleck, A.R. Zinsmeister, W.J. Sandborn The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients Gastroenterology 126 2004 19 31
274. T. Ljung, P. Karlen, D. Schmidt, P.M. Hellstrom, A. Lapidus, I. Janczewska, U. Sjoqvist, R. Lofberg Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County Gut 53 2004 849 853
275. G. Lichtenstein, R. Cohen, B. Feagan, W.J. Sandborn, B.A. Salzberg, D.M. Chen, R.H. Diamond Safety of infliximab in Crohn's disease: data from the 5000-patients TREAT Registry (abstr) Gastroenterology 126 2004 A54
276. M.A. Gardam, E.C. Keystone, R. Menzies, S. Manners, E. Skamene, R. Long, D.C. Vinh Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect Dis 3 2003 148 155
277. W.S. Mow, M.T. Abreu-Martin, K.A. Papadakis, H.E. Pitchon, S.R. Targan, E.A. Vasiliauskas High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy Clin Gastroenterol Hepatol 2 2004 309 313
278. American Thoracic Society, CDC, and Infectious Diseases Society of America Treatment of tuberculosis MMWR Morb Mortal Wkly Rep June 20 52 RR-11 2003 1 80
279. A. Cheifetz, M. Smedley, S. Martin, M. Reiter, G. Leone, L. Mayer, S. Plevy The incidence and management of infusion reactions to infliximab: a large center experience Am J Gastroenterol 98 2003 1315 1324
280. W.J. Sandborn, S.B. Hanauer Infliximab in the treatment of Crohn's disease: a user's guide for clinicians Am J Gastroenterol 97 2002 2962 2972
281. S. Vermeire, M. Noman, G. Van Assche, F. Baert, K. Van Steen, N. Esters, S. Joossens, X. Bossuyt, P. Rutgeerts Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study Gastroenterology 125 2003 32 39
282. J.B. Klapman, D. Ene-Stroescu, M.A. Becker, S.B. Hanauer A lupus-like syndrome associated with infliximab therapy Inflamm Bowel Dis 9 2003 176 178
283. C.N. Bernstein, J.F. Blanchard, E. Kliewer, A. Wajda Cancer risk in patients with inflammatory bowel disease: a population-based study Cancer 91 2001 854 862
284. A.J. Greenstein, R. Gennuso, D.B. Sachar, T. Heimann, H. Smith, H.D. Janowitz, A.H. Aufses Jr Extraintestinal cancers in inflammatory bowel disease Cancer 56 1985 2914 2921
285. J.D. Lewis, W.B. Bilker, C. Brensinger, J.J. Deren, D.J. Vaughn, B.L. Strom Inflammatory bowel disease is not associated with an increased risk of lymphoma Gastroenterology 121 2001 1080 1087
286. S.N. Gyde, P. Prior, J.C. Macartney, H. Thompson, J.A. Waterhouse, R.N. Allan Malignancy in Crohn's disease Gut 21 1980 1024 1029
287. A. Ekbom, C. Helmick, M. Zack, H.O. Adami Extracolonic malignancies in inflammatory bowel disease Cancer 67 1991 2015 2019
288. P.G. Persson, P. Karlen, O. Bernell, C.E. Leijonmarck, O. Brostrom, A. Ahlbom, G. Hellers Crohn's disease and cancer: a population-based cohort study Gastroenterology 107 1994 1675 1679
289. FDA Board Document. Update on the TNF-alpha blocking agent; 2003. Available at: FDA Board Document. SAFETY OF TNF BLOCKING AGENTS. Accessed Feb 13, 2006. www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_01_B-TNF.Briefing.htm.
290. G.R. Lichtenstein, R. Cohen, B. Feagan, W.J. Sandborn, B.A. Salzberg, D. Chen, M. Pritchard, R.H. Diamond Safety of infliximab and other Crohn's disease therapies-updated TREAT Registry data with over 10,000 patient-years of follow-up (abstr). Gastroenterology 128 2005 A-580
291. T. Jess, K.V. Winther, P. Munkholm, E. Langholz, V. Binder Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark Gastroenterology 122 2002 1808 1814
292. E.V. Loftus Jr., M.D. Silverstein, W.J. Sandborn, W.J. Tremaine, W.S. Harmsen, A.R. Zinsmeister Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival Gastroenterology 114 1998 1161 1168
293. R.G. Farmer, G. Whelan, V.W. Fazio Long-term follow-up of patients with Crohn's disease Relationship between the clinical pattern and prognosis Gastroenterology 88 1985 1818 1825
294. A. Ekbom, C.G. Helmick, M. Zack, L. Holmberg, H.O. Adami Survival and causes of death in patients with inflammatory bowel disease: a population-based study Gastroenterology 103 1992 954 960
295. D.A. Schwartz, M.J. Wiersema, K.M. Dudiak, J.G. Fletcher, J.E. Clain, W.J. Tremaine, A.R. Zinsmeister, I.D. Norton, L.A. Boardman, R.M. Devine, B.G. Wolff, T.M. Young-Fadok, N.N. Diehl, J.H. Pemberton, W.J. Sandborn A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas Gastroenterology 121 2001 1064 1072
296. C. Talbot, P.M. Sagar, M.J. Johnston, P.J. Finan, D. Burke Infliximab in the surgical management of complex fistulating anal Crohn's disease Colorectal Dis 7 2005 164 168
297. M. Regueiro, J. Valentine, S. Plevy, M.R. Fleisher, G.R. Lichtenstein Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease Am J Gastroenterol 98 2003 1821 1826
298. S. Kugathasan, A. Miranda, J. Nocton, B.A. Drolet, C. Raasch, D.G. Binion Dermatologic manifestations of Crohn disease in children: response to infliximab J Pediatr Gastroenterol Nutr 37 2003 150 154
299. A. Rispo, G. Lembo, L. Insabato, A. Cozzolino, G. Pesce, F. Castiglione Successful treatment of therapy-resistant metastatic Crohn's disease with infliximab Br J Dermatol 150 2004 1045 1046
300. J.M. Benitez-Del-Castillo, J.M. Martinez-De-La-Casa, E. Pato-Cour, R. Mendez-Fernandez, C. Lopez-Abad, M. Matilla, J. Garcia-Sanchez Long-term treatment of refractory posterior uveitis with anti-TNF alpha (infliximab) Eye 19 2005 841 845
301. C.C. Murphy, W.H. Ayliffe, A. Booth, D. Makanjuola, P.A. Andrews, D. Jayne Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis Ophthalmology 111 2004 352 356
302. T.I. Temekonidis, Y. Alamanos, S.N. Nikas, D.V. Bougias, A.N. Georgiadis, P.V. Voulgari, A.A. Drosos Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study Ann Rheum Dis 62 2003 1218 1220
303. A. Lupascu, A. Armuzzi, B. De Pascalis, E. Carloni, E.C. Lauritano, A. Gasbarrini, P. Pola, A. Gasbarrini Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms Dig Liver Dis 36 2004 423 425
304. I. Kaufman, D. Caspi, D. Yeshurun, I. Dotan, M. Yaron, O. Elkayam The effect of infliximab on extraintestinal manifestations of Crohn's disease Rheumatol Int 25 2005 406 410
305. H.J. Freeman, J.E. Davis, M.E. Prest, E.J. Lawson Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn's disease Can J Gastroenterol 18 2004 687 690
306. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, J.T. Willerson Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 2003 3133 3140
307. N. Mohan, E.T. Edwards, T.R. Cupps, P.J. Oliverio, G. Sandberg, H. Crayton, J.R. Richert, J.N. Siegel Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides Arthritis Rheum 44 2001 2862 2869
308. S.A. Nanavati, G.A. Ergun, J.T. Schwartz Avoiding infliximab in the treatment of Crohn's disease in patients with multiple sclerosis Am J Gastroenterol 98 2003 2333 2334
309. C.W. Thomas Jr, B.G. Weinshenker, W.J. Sandborn Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease Inflamm Bowel Dis 10 2004 28 31
310. B.Y. Strong, B.C. Erny, H. Herzenberg, K.J. Razzeca Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease Ann Intern Med 140 2004 W34
311. L.J. Mejico Infliximab-associated retrobulbar optic neuritis Arch Ophthalmol 122 2004 793 794
312. W.J. Sandborn, E.V. Loftus Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease Gut 53 2004 780 782
313. W.J. Tremaine, S.B. Hanauer, S. Katz, B.D. Winston, J.G. Levine, T. Persson, A. Persson Budesonide CIR United States Study Group Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States Am J Gastroenterol 97 2002 1748 1754
314. Entocort EC [package insert]. Wayne, PA: AstraZeneca Pharmaceuticals, 2005.
315. Y. Bouhnik, M. Lemann, J.Y. Mary, G. Scemama, R. Tai, C. Matuchansky, R. Modigliani, J.C. Rambaud Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine Lancet 347 1996 215 219